Today’s presentation in this post-ASCO Miami meeting is going to be about reviewing all the new results on CML and CLL as well as MDS. Pretty much I’m going to really discuss a few interesting presentations that were really done at Chicago last May. The first one is the new update of a new trial that is being revamped with a drug called Bosulif, bosutinib, and a randomised trial in comparison with imatinib.
The second one is the update, five years update, of another drug also being used in our practice. This drug is ponatinib, Iclusig, with a long-term follow-up in a very, very interesting trial that we’ve been following for the last year. [?? 0:50] and in chronic lymphocytic leukaemia in this ASCO we have seen the four years update of the RESONATE trial that compared ibrutinib with ofatumumab as well as a new trial with a different monoclonal antibody, anti-CD20, ublituximab, in combination with ibrutinib in comparison with ibrutinib alone.
This is pretty much the concentration of the more interesting abstracts that were presented and in MDS this year was not really a significant advance so I won’t really discuss much about.